Your session is about to expire
← Back to Search
MAPK Inhibitors + Pembrolizumab for Melanoma
Study Summary
This trial is testing the combination of these drugs to see if it is more effective in treating unresectable or metastatic melanoma than pembrolizumab alone.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I haven't had chemotherapy or radiation in the last 2 weeks and have recovered from any side effects.I have a history of retinal vein blockage or detachment.You are allergic to pembrolizumab or any of its ingredients.I have been treated with specific cancer drugs for advanced or inoperable disease.I am not currently taking any cancer treatment drugs.I haven't had cancer treatment with monoclonal antibodies in the last 4 weeks or have recovered from their side effects.I have a history of active tuberculosis.I have had cancer before, but it fits the allowed exceptions.I am 18 years old or older.My organ and bone marrow functions are normal.I have an autoimmune disease treated with medication in the last 2 years.I do not have any uncontrolled illnesses.I have previously been treated with ipilimumab, anti-PD1, or high-dose IL-2.I have not received a live vaccine in the last 30 days.I do not have any symptoms or untreated brain or spinal cord lining disease.I am willing to have multiple biopsies of my tumor.I am not HIV-positive or on antiretroviral therapy.I have an immune system disorder or have been on steroids or other immune-weakening medicines in the last week.My melanoma cannot be removed by surgery and has spread.I have a tumor that can be measured with a scan.I have not had major surgery in the last 2 weeks.I am not taking any medication for epilepsy that increases enzyme activity.You have ongoing Hepatitis B or Hepatitis C infection.I know my cancer's BRAFV600 mutation status.I have had pneumonitis treated with steroids or have it now.I do not have symptoms from brain metastases.I am fully active and can carry on all my pre-disease activities without restriction.
- Group 1: BRAFV600 mutant
- Group 2: BRAFV600 wild type
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Could you detail the other research initiatives related to Pembrolizumab?
"At present, there are 1,045 trials for Pembrolizumab live on a global scale. Out of these studies, 128 are in the third phase and Rochester, Minnesota houses many of them. Additionally, 41,395 locations have been identified as running clinical studies with this drug."
What is the upper boundary for participant numbers in this clinical experiment?
"This clinical trial has since ended its recruitment process, with the initial post being published on November 27th 2017 and last updated August 30th 2022. For those looking for other studies to join, there are 765 trials searching for patients dealing with melanoma and 1,045 trials actively recruiting participants interested in Pembrolizumab."
Does the research team have open enrollment for participants?
"Currently, no more participants are being sought for this trial. Initially posted on November 27th 2017 and most recently edited August 30th 2022, the study is now closed. However, there remain 765 clinical trials that recruit patients with melanoma and 1045 studies recruiting those eligible to receive Pembrolizumab treatment."
Are there any adverse effects to utilizing Pembrolizumab?
"Our assessment of Pembrolizumab's safety is a 2 as it is currently undergoing Phase 2 trials, which indicate the presence of some data on its safety but not yet any evidence concerning its efficacy."
What maladies is Pembrolizumab regularly employed to ameliorate?
"Pembrolizumab is the primary drug of choice for treating malignant neoplasms. This medication can also be effective at managing unresectable melanoma, microsatellite instability high, and chemotherapy-induced illness progression."
Share this study with friends
Copy Link
Messenger